The trial achieved each its Most important endpoints, with semaglutide two.four mg demonstrating statistically substantial and top-quality advancements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH in comparison with placebo.oneSem